
	Where results make sense

Topic: Antiplatelet drug

Related Topics

Phosphodiesterase inhibitor

Abciximab

Fibrinolytic

Pharmacology

Clopidogrel

Aspirin

Fibrinolysis

	RedOrbit - Health - Antiplatelet Therapy (Site not responding. Last check: 2007-10-13)
		Antiplatelet drugs are of use in cardiovascular and cerebrovascular disease and have been shown to reduce the incidence of vascular events such as myocardial infarction (MI) or stroke (Antiplatelet Triallists Collaboration 1994), of which older people are at greater risk.
		Antiplatelet drugs reduce the aggregation of platelets in the blood which if left untreated in an atherosclerotic vessel may lead to thromboembolism formation and subsequent cardiovascular events such as Ml or stroke.
		Antiplatelet therapy has been shown to be of benefit in all types of vascular disease in the prevention of vascular events such as Ml and stroke (Antiplatelet Triallists Collaboration 1994).
	www.redorbit.com /news/display?id=102871 (0 words)

	Harvard Gazette: New drug therapy cuts risk of second heart attack
		The new therapy adds a fourth drug to the three-drug regimen that is frequently prescribed after a heart attack to break up clots that block arteries carrying the heart's critical blood supply.
		The addition of the fourth drug - an antiplatelet medication called clopidogrel, marketed commercially under the name Plavix - reduced the odds of a second heart attack by 31 percent and also reduced the odds of dying from heart-related causes and of needing emergency bypass surgery to restore blood flow to the heart.
		Though bleeding is a concern with antiplatelet medications such as aspirin, the rate of major bleeding in the clopidogrel group was 1.3 percent, similar to the 1.1 percent in the placebo group.
	www.hno.harvard.edu /gazette/2005/03.24/15-drug.html (0 words)

	University of Texas Houston Departmennt of Neurology - STAT
		Antiplatelet drugs are prescribed to prevent blood clots from forming or growing.
		Antiplatelet agents attack the very beginning of the clot formation process by inhibiting an important enzyme necessary for platelet adhesion and activation.
		The drug has been studied in a large, multi-center, placebo-controlled clinical trial (European Stroke Prevention Study 2) comparing it to both dipyridamole and aspirin alone for second stroke prevention in patients who had experienced a recent ischemic stroke or TIA.
	www.houstonstroke.com /reduction/clotpreventionmedication.html (0 words)

	Australian Prescriber - Warfarin,antiplatelet drugs and their interactions
		The importance of platelets in thrombus formation is evident by the therapeutic efficacy of antiplatelet drugs in thromboembolic disease, especially arterial vascular disease.
		While generally the combination is avoided, antiplatelet drugs and warfarin are sometimes deliberately used in patients with embolic phenomena from prosthetic and diseased heart valves or those with refractory arterial ischaemia.
		If antiplatelet drugs are to be concurrently used, it is prudent to keep the patient’s INR at the lower end of the desired target range.
	www.australianprescriber.com /magazine/25/4/81/5 (0 words)

	Stroke, Conventional Treatments for Stroke, Drug Therapy, Holisticonline.com
		If a doctor administers a clot-dissolving drug within 3 hours of an ischemic stroke, normal blood flow can often be restored, and the risk of death or permanent disability drops by about 30 percent.
		Antiplatelet drugs prevent clotting by decreasing the activity of platelets, blood cells that contribute to the clotting property of blood.
		These drugs halt the stroke by dissolving the blood clot that is blocking blood flow to the brain.
	www.holistic-online.com /Remedies/Heart/stroke_conv_drug-therapy.htm (0 words)

	Drug Bulletin on Drug Use Evaluation - November 2004
		This topic meets the predefined criteria for a critical drug issue as diabetes has a high prevalence in First Nations and Inuit communities, the drugs used in diabetes management have large variations in use and these drugs have shown positive and measurable impacts on health outcomes.
		The purpose of this drug use evaluation was therefore to determine the rate of prescribing of ACE inhibitor and antiplatelet therapy among diabetes claimants of the NIHB Program.
		Antiplatelet drug therapy was dispensed to approximately 43% of diabetes claimants of the NIHB Program who were aged >30 years.
	www.hc-sc.gc.ca /fnih-spni/pubs/drug-med/2004_nov_due-eum/index_e.html (0 words)

	Antiplatelets - Page 2
		Antiplatelets are medications that inhibit the activity of platelets, which help the blood clot after injury.
		To help prevent this, physicians may prescribe antiplatelets, which inhibit platelets' clotting activity in patients who are at high risk for developing a thrombus within their blood vessels.
		While antiplatelets are a valuable preventive tool when used properly, they can cause serious bleeding in some people, and their activity may be affected by a wide range of other medications and substances.
	heart.healthcentersonline.com /bloodclot/antiplatelets2.cfm (0 words)

	Checking for Possible Herb-Drug Interactions
		Alternatively, an herb might produce an effect that is contrary to the effect desired for the drug, thereby reducing the drug effect; or, an herb might produce the same kind of effect as the drug and give an increase in the drug effect (without increasing the amount of the drug).
		If the drug effect is increased or prolonged by the herb, it is implied that the herb has a similar effect, even though it may have a different mechanism.
		Non-steroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, have the potential to interact with herbal supplements that are known to possess antiplatelet activity (ginkgo, garlic, ginger, bilberry, dong quai, feverfew, ginseng, turmeric, meadowsweet and willow), with those containing coumarin (chamomile, motherwort, horse chestnut, fenugreek and red clover) and with tamarind, enhancing the risk of bleeding.
	www.itmonline.org /arts/herbdrug2.htm (0 words)

	Aspirin protects patients at high risk of heart attack or stroke (Site not responding. Last check: 2007-10-13)
		Aspirin (or another antiplatelet drug) protects patients at high risk of serious vascular events, such as heart attack or stroke, and should be considered routinely for all such patients, concludes a study in this week's BMJ.
		They found that antiplatelet therapy reduced the risk of any serious vascular event by about one quarter; risk of non-fatal heart attack was reduced by one third, non-fatal stroke by one quarter, and vascular death by one sixth.
		In each of these high risk categories, the benefits of antiplatelet therapy far outweighed any hazards, yet only about half (or less) of all patients with a history of heart attack, angina, or heart disease are currently receiving antiplatelet therapy, say the authors.
	www.eurekalert.org /pub_releases/2002-01/bmj-app010902.php (0 words)

	Drug Trio May Cut Stroke Severity - Health and Medical Information produced by doctors - MedicineNet.com
		Prompt treatment for stroke is a must, since some clot-busting stroke drugs must be given within a few hours of the start of stroke symptoms.
		That group included 47 patients who were only taking an antiplatelet, 29 taking an ACE inhibitor and an antiplatelet, 14 taking an antiplatelet and a statin, and 20 taking all three types of drugs.
		Stroke severity on admission was significantly lower in patients taking all three types of drugs than in patients taking none of those drugs, antiplatelets alone, antiplatelets and statins, or antiplatelets and ACE inhibitors.
	www.medicinenet.com /script/main/art.asp?articlekey=61202 (0 words)

	Ticlopidine/Vera/1997
		Ticlopidine is a new specific and potent antiplatelet drug that inhibits platelet aggregation induced by adenosine diphosphate and by thrombin.
		Antiplatelet therapy was also associated with a lower rate of cardiac events, such as death, myocardial infarction, and the need for repeated intervention.
		It is obvious that although this drug may contain possible side effects, the decision to use this drug depends entirely on the individual's medical condition.
	wwwchem.csustan.edu /chem4400/SJBR/Vera97.htm (0 words)

	SJW - Herbs & Supplements - Drug Library - DrugDigest
		John's wort may activate enzymes that break down certain drugs; therefore, it may interfere with the effects of drugs used to suppress the immune system after organ transplants or in other conditions.
		Drugs known as psoralens cause the skin to be excessively sensitive to sunlight.
		When St. John's wort is used with prescription drugs that promote sleepiness, the effects of the drug may be exaggerated, resulting in sedation or mental impairment.
	www.drugdigest.org /DD/DVH/HerbsInteractions/0,3926,4049\|SJW,00.html (0 words)

	Antiplatelets - Page 1
		Antiplatelet medications may be prescribed for heart patients to reduce the likelihood that platelets will gather (aggregate) and form potentially harmful blood clots.
		Antiplatelet medications are available as both prescription and over-the-counter medications.
		Children should never be given antiplatelets unless under the direction of a physician.
	heart.healthcentersonline.com /bloodclot/antiplatelets.cfm (0 words)

	Drug-eluting stent - Wikipedia, the free encyclopedia
		However, the antiplatelet therapy may be insufficient to fully prevent clots; these and the cell proliferation may cause the standard (“bare-metal”) stents to become blocked.
		These typically have been drugs already in use as anti-cancer drugs or drugs that suppress the immune system, although new drugs are being developed specifically for drug-eluting stents.
		Both drugs currently in use were previously developed for other purposes; their use to prevent in-stent proliferation is relatively new.
	en.wikipedia.org /wiki/Drug-eluting_stent (0 words)

	Study shows combining antiplatelet drug Abciximab with clot-buster is effective in treating heart-attack patients
		Nearly all heart attacks are caused by a blood clot that obstructs the flow of blood to the heart, thereby depriving it of oxygen and nutrients.
		Clot-busting drugs, also known as thrombolytics, currently are the standard therapy for treating heart attacks.
		These drugs have been shown to be effective in breaking down the clots, restoring blood flow, and reducing the risk of death.
	www.eurekalert.org /pub_releases/1999-05/UNKN-Ssca-310599.php (0 words)

	Antiplatelet and anticoagulation for patients with prosthetic heart valves
		Oral anticoagulation plus an antiplatelet drug is better than oral anticoagulants alone for reducing the risk of death or blood clots (thromboembolism) after heart valve replacement.
		Drugs that affect the platelets, such as aspirin, are not effective alone but may add benefit to the blood thinners.
		Adding antiplatelet therapy, either dipyridamole or low-dose aspirin, to oral anticoagulation decreases the risk of systemic embolism or death among patients with prosthetic heart valves.
	www.cochrane.org /reviews/en/ab003464.html (0 words)

	Anti-coagulant and Anti-platelet Drugs \| Principal Health News
		Drug used to prevent clot formation or to prevent a clot that has formed from enlarging.
		Anticoagulant drugs fall into three groups: inhibitors of clotting factor synthesis, inhibitors of thrombin and antiplatelet drugs.
		Drug that inhibits platelets from aggregating to form a plug.
	www.principalhealthnews.com /topic/anticoagulant (0 words)

	0599jc
		The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
		Purpose: Cilostazol is an antiplatelet drug which increases the cyclic AMP levels in platelets via inhibition of the cyclic AMP phosphodiesterase.
		A new drug to treat gastroparesis, or even to slow the development of gastroparesis in people who are beginning to have symptoms is now in clinical trials, notes Dr. Hare.
	www.thai-otsuka.co.th /pxnews/0599jc.htm (0 words)

	Teaching Brief® - MedPage Today
		Explain to interested patients that data reported this week are based on meta-analyses and registries, not randomized clinical trials, and that these studies are preliminary, not having been published in peer reviewed journals.
		That device is just one of a handful of second- and third- generation drug-eluting stents wending their way through the approval process.
		Weighing the darker and the brighter sides of drug eluting stents has been the focus of heated discussions here, inside and outside the sessions.
	www.medpagetoday.com /tbprint.cfm?tbid=4049 (0 words)

	Using clopidogrel bisulfate: A new antiplatelet drug Nurse Practitioner - Find Articles
		Clopidogrel bisulfate (Plavix) is the newest antiplatelet drug available for patients with documented atherosclerotic disease.
		Antiplatelet drugs are instrumental in preventive therapy, and clopidogrel bisulfate is one of the most recent approvals in this class.
		Low-dose aspirin and other antiplatelet drugs have reduced the incidence of additional myocardial infarction, stroke, and cardiovascular mortality by about 25% in patients with established cardiovascular disease.5,6
	www.findarticles.com /p/articles/mi_qa3958/is_199909/ai_n8860142 (0 words)

	Antiplatelet Drug May Help Aspirin Prevent Stroke
		A number of trials have established the role of the combination in heart conditions, said Dr. Marc S. Sabatine, an associate physician in the cardiovascular division of Brigham and Women's Hospital in Boston, and a leader of one such trial.
		That trial, the results of which were reported earlier this year, showed that the combined drug treatment reduced the death rate in people who suffered major heart attacks, Sabatine said.
		And the two-drug regimen reduces the death rate by 20 percent in people who suffer smaller heart attacks or have unstable angina, the chest pain that is a major marker of coronary trouble, he said.
	www.healthatoz.com /healthatoz/Atoz/news/hs525333.jsp (0 words)

	Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial ... (Site not responding. Last check: 2007-10-13)
		Antiplatelet therapy is effective for short term treatment of patients with suspected acute myocardial infarction and unstable angina
		Absolute effects of antiplatelet therapy on various outcomes in patients with (a) previous myocardial infarction (12 trials); (b) acute myocardial infarction (15 trials); (c) previous stroke or transient ischaemic attack (21 trials); and (d) acute (presumed ischaemic) stroke (seven trials).
		Utsumi H. Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction.
	www.bmj.com /cgi/content/full/324/7329/71 (0 words)

	Gathering intelligence on antiplatelet drugs: the view from 30 000 feet -- Reilly and FitzGerald 324 (7329): 59 -- BMJ
		of antiplatelet drugs in such populations is arguable.
		III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients.
		Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
	www.bmj.com /cgi/content/full/324/7329/59 (0 words)

	Antiplatelet drug discontinuation is a risk factor for ischemic stroke -- Sibon and Orgogozo 62 (7): 1187 -- Neurology
		Antiplatelet drug discontinuation is a risk factor for ischemic stroke -- Sibon and Orgogozo 62 (7): 1187 -- Neurology
		Antiplatelet drug discontinuation is a risk factor for ischemic stroke
		Antiplatelet drugs (APD) are widely used in the prevention of
	www.neurology.org /cgi/content/abstract/62/7/1187 (0 words)

	Drug May Aid Aspirin After Ministroke
		The drug combination is aspirin and the antiplatelet drug dipyridamole.
		In the aspirin-plus-dipyridamole group, 470 patients stopped taking their drugs, compared to 184 assigned to aspirin alone.
		Headaches, a possible side effect of dipyridamole, were the main reason for the dropouts in the drug combination group, the study shows.
	www.webmd.com /content/article/122/114704?src=RSS_PUBLIC (0 words)

	Role Of Newer Antiplatelet Drugs In Percutaneous Coronary Interventions (Site not responding. Last check: 2007-10-13)
		The incidence of adverse effects was 4.6% in the clopidogrel group compared to 9.1 per cent in the ticlopidine group leading to discontinuation of therapy in 3.5 per cent in the clopidogrel group compared to 8.2 per cent in the ticlopidine group which was statistically significant.
		Further it was seen that the anticoagulant used to assess the antiplatelet efficacy of eptifibatide in vitro, overestimated its efficacy.
		The drug was used in doses of 10 µg/kg over 3 minutes before the procedure followed by 0.15 µg/kg/min for 36 hours.
	www.indegene.com /Car/FeatArt/indCar_Fet_13-10-2000_1.asp (0 words)

	News: Lipicard Technologies Study: Antiplatelet Drugs -- Blindfolded and Poisoned; Are You Moving Around Blindfolded ...
		This is because there is currently no better drug available, no simple and accurate measurement of clotting time exists and Doctors have no clue whether Aspirin/ Clopidogrel is actually working for you.
		After its antiplatelet activity was discovered in late 1980s, millions started taking it indefinitely for life-long cardio-protection.
		Platrol(R) is the first safe antiplatelet drug being developed for cardio-protection.
	www.genengnews.com /news/bnitem.aspx?name=3457084 (0 words)

	Know Stroke: Available Therapies - Medications
		The most popular classes of drugs used to prevent or treat stroke are antithrombotics (antiplatelet agents and anticoagulants), thrombolytics, and neuroprotective agents.
		The National Institute for Neurological Disorders and Stroke (NINDS) sponsors a wide range of clinical trials to determine the effectiveness of antiplatelet drugs for stroke prevention.
		The NINDS has sponsored several trials to test the efficacy of anticoagulants versus antiplatelet drugs.
	www.peacehealth.org /oregon/KnowStroke/Therapies_Meds.htm (0 words)

	Phase II Data Suggest Antiplatelet Drug ReoPro® (abciximab) May Benefit Stroke Patients Without Increased Risk of ...
		Atlanta, GA (November 7, 1999) – The antiplatelet drug ReoPro® (abciximab) can improve clinical function in patients with acute ischemic stroke without an increased risk of intracranial bleeding, even among patients treated up to 24 hours after symptom onset, researchers reported here today at the 72nd Scientific Sessions of the American Heart Association.
		Although ReoPro® is a potent antiplatelet drug and therefore can increase the risk of bleeding, none of the patients in the stroke trial suffered from symptomatic intracranial hemorrhage (ICH), a potentially fatal side effect of current therapy.
		The drug was developed by Centocor of Malvern, PA, and is manufactured by Centocor B.V. in Leiden, the Netherlands.
	www.jnj.com /news/jnj_news/20020307_2136.htm (0 words)

Try your search on: Qwika (all wikis)